fangchinoline has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ao, W; Chan, WN; Chen, B; Cheung, AHK; He, M; Huang, H; Kang, W; Ke, J; Li, S; Liang, Q; Ma, BBY; Song, Y; To, KF; Xiao, J; Xie, F; Zhan, Y; Zhang, Y; Zhou, S | 1 |
| Chen, JS; Gao, XZ; Guo, X; Han, JL; Liu, C; Sun, H; Sun, JY; Wang, MX; Wang, Z; Zhang, K | 1 |
2 other study(ies) available for fangchinoline and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
Topics: Animals; Benzylisoquinolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Fangchinoline derivatives inhibits PI3K signaling in vitro and in vivo in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2023 |